Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
更新：艾伯维以最高14.5亿美元的期权押注热门的泛RAS赛道，拟收购克斯特罗治疗(Kestrel Therapeutics)

The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers.
泛RAS领域持续升温，艾伯维签约押注，谋求进入这一有望大幅改变某些癌症治疗格局的赛道。